tetano
Editor, Senior Moderator
Virol J
. 2021 Jul 1;18(1):134.
doi: 10.1186/s12985-021-01599-9.
Persistence of SARS-CoV-2 RNA in the nasopharyngeal, blood, urine, and stool samples of patients with COVID-19: a hospital-based longitudinal study
Farahnaz Joukar[SUP] 1 [/SUP], Tofigh Yaghubi Kalurazi[SUP] 2 [/SUP], Mahmoud Khoshsorour[SUP] 3 [/SUP], Sonbol Taramian[SUP] 2 [/SUP], Lida Mahfoozi[SUP] 4 [/SUP], Heydar Ali Balou[SUP] 5 [/SUP], Alireza Jafarinezhad[SUP] 6 [/SUP], Aydin Pourkazemi[SUP] 7 [/SUP], Ezat Hesni[SUP] 7 [/SUP], Mehrnaz Asgharnezhad[SUP] 8 [/SUP], Mohammad Shenagari[SUP] 9 [/SUP], Issa Jahanzad[SUP] 10 [/SUP], Mohammadreza Naghipour[SUP] 3 [/SUP], Saman Maroufizadeh[SUP] 11 [/SUP], Fariborz Mansour-Ghanaei[SUP] 12 [/SUP]
Affiliations
Abstract
Background: The persistence of severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) RNA in the body fluids of patients with the novel coronavirus disease 2019 (COVID-19) may increase the potential risk of viral transmission. There is still uncertainty on whether the recommended quarantine duration is sufficient to reduce the risk of transmission. This study aimed to investigate the persistence of SARS-CoV-2 RNA in the nasopharyngeal, blood, urine, and stool samples of patients with COVID-19.
Methods: In this hospital-based longitudinal study, 100 confirmed cases of COVID-19 were recruited between March 2020 and August 2020 in Guilan Province, north of Iran. Nasopharyngeal, blood, urine, and stool samples were obtained from each participant at the time of hospital admission, upon discharge, 1 week after discharge, and every 2 weeks until all samples were negative for SARS-CoV-2 RNA by reverse transcription-polymerase chain reaction (RT-PCR) assay. A survival analysis was also performed to identify the duration of viral persistence.
Results: The median duration of viral RNA persistence in the nasopharyngeal samples was 8 days from the first positive RT-PCR result upon admission (95% CI 6.91-9.09); the maximum duration of viral shedding was 25 days from admission. Positive blood, urine, and stool RT-PCR results were detected in 24%, 7%, and 6% of the patients, respectively. The median duration of viral persistence in the blood, urine, and stool samples was 7 days (95% CI 6.07-7.93), 6 days (95% CI 4.16-8.41), and 13 days (95% CI 6.96-19.4), respectively. Also, the maximum duration of viral persistence in the blood, urine, and stool samples was 17, 11, and 42 days from admission, respectively.
Conclusion: According to the present results, immediately after the hospitalized patients were discharged, no evidence of viral genetic materials was found. Therefore, appropriate treatments were selected for the patients at this hospital. However, we recommend further investigations on a larger sample size in multi-center and prospective randomized controlled trials (RCTs) to evaluate the effects of different drugs on the shedding of the virus through body secretions.
Keywords: COVID-19; Persistence; RNA; RT-PCR; SARS-CoV-2.
. 2021 Jul 1;18(1):134.
doi: 10.1186/s12985-021-01599-9.
Persistence of SARS-CoV-2 RNA in the nasopharyngeal, blood, urine, and stool samples of patients with COVID-19: a hospital-based longitudinal study
Farahnaz Joukar[SUP] 1 [/SUP], Tofigh Yaghubi Kalurazi[SUP] 2 [/SUP], Mahmoud Khoshsorour[SUP] 3 [/SUP], Sonbol Taramian[SUP] 2 [/SUP], Lida Mahfoozi[SUP] 4 [/SUP], Heydar Ali Balou[SUP] 5 [/SUP], Alireza Jafarinezhad[SUP] 6 [/SUP], Aydin Pourkazemi[SUP] 7 [/SUP], Ezat Hesni[SUP] 7 [/SUP], Mehrnaz Asgharnezhad[SUP] 8 [/SUP], Mohammad Shenagari[SUP] 9 [/SUP], Issa Jahanzad[SUP] 10 [/SUP], Mohammadreza Naghipour[SUP] 3 [/SUP], Saman Maroufizadeh[SUP] 11 [/SUP], Fariborz Mansour-Ghanaei[SUP] 12 [/SUP]
Affiliations
- PMID: 34210325
- DOI: 10.1186/s12985-021-01599-9
Abstract
Background: The persistence of severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) RNA in the body fluids of patients with the novel coronavirus disease 2019 (COVID-19) may increase the potential risk of viral transmission. There is still uncertainty on whether the recommended quarantine duration is sufficient to reduce the risk of transmission. This study aimed to investigate the persistence of SARS-CoV-2 RNA in the nasopharyngeal, blood, urine, and stool samples of patients with COVID-19.
Methods: In this hospital-based longitudinal study, 100 confirmed cases of COVID-19 were recruited between March 2020 and August 2020 in Guilan Province, north of Iran. Nasopharyngeal, blood, urine, and stool samples were obtained from each participant at the time of hospital admission, upon discharge, 1 week after discharge, and every 2 weeks until all samples were negative for SARS-CoV-2 RNA by reverse transcription-polymerase chain reaction (RT-PCR) assay. A survival analysis was also performed to identify the duration of viral persistence.
Results: The median duration of viral RNA persistence in the nasopharyngeal samples was 8 days from the first positive RT-PCR result upon admission (95% CI 6.91-9.09); the maximum duration of viral shedding was 25 days from admission. Positive blood, urine, and stool RT-PCR results were detected in 24%, 7%, and 6% of the patients, respectively. The median duration of viral persistence in the blood, urine, and stool samples was 7 days (95% CI 6.07-7.93), 6 days (95% CI 4.16-8.41), and 13 days (95% CI 6.96-19.4), respectively. Also, the maximum duration of viral persistence in the blood, urine, and stool samples was 17, 11, and 42 days from admission, respectively.
Conclusion: According to the present results, immediately after the hospitalized patients were discharged, no evidence of viral genetic materials was found. Therefore, appropriate treatments were selected for the patients at this hospital. However, we recommend further investigations on a larger sample size in multi-center and prospective randomized controlled trials (RCTs) to evaluate the effects of different drugs on the shedding of the virus through body secretions.
Keywords: COVID-19; Persistence; RNA; RT-PCR; SARS-CoV-2.